Shares of Bruker Co. (NASDAQ:BRKR – Get Free Report) have been given a consensus recommendation of “Hold” by the five analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $80.00.
A number of analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price target on shares of Bruker from $70.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, October 17th. Wolfe Research started coverage on Bruker in a report on Wednesday, December 13th. They issued an “outperform” rating and a $80.00 target price on the stock. Finally, Wells Fargo & Company began coverage on Bruker in a research note on Tuesday, December 19th. They set an “equal weight” rating and a $72.00 price target for the company.
Bruker Stock Up 2.9 %
Bruker Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, December 1st were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.20 annualized dividend and a yield of 0.27%. Bruker’s payout ratio is presently 9.22%.
Institutional Investors Weigh In On Bruker
Hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Bruker by 4.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 747,802 shares of the medical research company’s stock valued at $54,948,000 after buying an additional 34,355 shares during the period. M&T Bank Corp grew its position in Bruker by 5.6% in the 4th quarter. M&T Bank Corp now owns 4,278 shares of the medical research company’s stock valued at $314,000 after acquiring an additional 228 shares during the last quarter. Natixis Advisors L.P. increased its stake in Bruker by 75.3% in the fourth quarter. Natixis Advisors L.P. now owns 77,303 shares of the medical research company’s stock worth $5,679,000 after purchasing an additional 33,204 shares during the period. New York Life Investment Management LLC purchased a new stake in Bruker in the fourth quarter worth $823,000. Finally, Buckhead Capital Management LLC bought a new stake in shares of Bruker during the fourth quarter worth $1,634,000. Hedge funds and other institutional investors own 79.78% of the company’s stock.
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies.
- Five stocks we like better than Bruker
- Canada Bond Market Holiday: How to Invest and Trade
- Is the dip in Atlassian stock a sneaky buy opportunity?
- What is the Australian Securities Exchange (ASX)
- Caterpillar stock hits new highs; time to ring the register?
- P/E Ratio Calculation: How to Assess Stocks
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.